Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple exercise routine strengthen bones in thalassemia?

NCT ID NCT07064941

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial investigates whether a 12- to 36-week program of aerobic and strength exercises can improve body composition, muscle function, and bone density in adolescents and adults with thalassemia. Participants will follow a self-directed routine of 30 minutes of exercise, 5 days per week, with a choice of activities like brisk walking or strength exercises. The study compares changes during a usual-activity period to changes during the exercise period to see if weight-bearing activity can benefit bone health in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a self-directed exercise program combining aerobic and strength training
What this could lead to
If it works, this could point toward a simple, drug-free way to strengthen bones and muscles in people with thalassemia.
What could go wrong
This is a very small, early trial with only 20 participants. The exercise is self-directed, so adherence may vary, and results may not apply to everyone with thalassemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 14 - 40 years * BMD Z-score at any skeletal site \< -1.0 * Diagnosed with thalassemia (any genotype, regardless of transfusion dependency) * Vitamin D (25-Hydroxy) drawn within the previous 12 months \>20 ng/mL * English speaking, able to consent Exclusion Criteria: * Patients who self-identify as 'exercisers' e.g. routinely exercise for minimum of 45 min/day, 5x/week * Pregnant (unable to conduct bone density measurements in pregnant females) * Hypogonadal, must be on replacement sex hormone therapy for min of 6 months * Cardiac T2\* by Magnetic Resonance Imaging of \<20 ms (e.g. evidence of cardiac iron overload) * Recent long bone or vertebral fracture (within the last 6 months) * Cognitive impairment limiting ability to understand instructions during orientation * Other conditions known to influence bone health or body composition as determined by the investigator * Patients at risk for cardiovascular disease yet have not received a routine cardiology assessment within the previous 12 months * Bone medication (e.g. Zometa, Prolia, Forteo) use in previous 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thalassemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thalassemia

Contacts and locations

Locations

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California, 94609, United States

  • University of California, San Francisco

    Oakland, California, 94609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.